Incretin-based Therapies, Nutrition, and Physical Activity

What this study is about

The goal of this clinical trial is to evaluate whether combining a six-month structured lifestyle intervention (physical activity and nutrition) with incretin-based weight-loss medication improves preservation of muscle mass and physical function in adults living with obesity, compared with medication alone, and to assess the feasibility of a collaborative hospital-community care model. This one-year pilot study will recruit 120 adults aged 18-70 years with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with at least one comorbidity) receiving routine obesity care at the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval. All participants will initiate physician-prescribed incretin-based therapy as part of standard care. The intervention group will receive medication plus a six-month structured lifestyle program delivered in collaboration with an exercise facility, including supervised strength-focused exercise and bi-monthly nutrition counseling, followed by a six-month consolidation phase. The control group will receive medication alone. Outcomes will be assessed at baseline and at 3, 6, and 12 months. Participants will be randomly assigned in a 1:1 ratio to either the medication-only group or the combined medication and lifestyle intervention group. Participants randomized in the medication only group will receive a personalized consult with both a registered dietician and kinesiologist at the end of the study.

Who can join (things the study team will check)

✅ You may be able to join if…

• Adults aged 18 to 70 years
• Prescribed, but not yet initiated, incretin-based pharmacotherapy [e.g., GLP-1 receptor agonist or dual GIP/GLP1 agonist] living with obesity, defined as:
  • BMI >30 kg/m2, or
  • BMI >27 kg/m2 with presence of comorbidities (e.g., type II diabetes, hypertension, hypercholesterolemia)

🚫 You may not be able to join if…

• Medical contraindications to physical activity practice (e.g., unstable cardiovascular disease, severe orthopedic limitation)
• Prior or ongoing incretin-based therapy or history of bariatric surgery
• Pregnancy, current breastfeeding or planned pregnancy during the study period
• Implemented medical devices (e.g. pacemaker, defibrillator)
• Chronic conditions affecting protein metabolism or nutrition (e.g., advanced kidney disease, active cancer)

Where this trial is running

• Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Quebec, Canada
• Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Quebec, Canada

Who to contact

Elisa Marin-Couture, Kin, PhD · 1-418-656-8711 · elisa.marin-couture.1@ulaval.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07409831.